More to think about . . .
H1N1 flu could fill hospital beds
Trust for America's Health (TFAH) Report
"African-Americans and Hispanics are more likely to have severe cases of H1N1 because they suffer from more underlying chronic conditions, like asthma and diabetes, at the same time many significant gaps remain in systems for reaching minority communities.
For instance, emergency preparedness information is often disseminated on the Internet, which many people do not have access to, and there is limited availability of non-English information."
(From the TFAH Report)
More information on Swine Flu (H1N1) - Talking Technology with Leroy Jones, Jr.:
Formulation Substitution (or Therapeutic Equivalency)
Definition: As patients and prescription benefit plans seek to lower their healthcare costs, they may substitute a less expensive therapeutically equivalent drug for a more costly drug.
Formulation substitution can include switching from a brand-name drug to a generic drug, switching from one generic drug to another generic drug, or (rather uncommonly) switching from a generic drug to a brand-name drug.
In most states, formulation substitution is allowed and encouraged, provided that the replacement formulation is deemed to be "therapeutically equivalent" to the innovator formulation by the Food and Drug Administration (FDA).
The FDA publishes a list of drug products and equivalents entitled Approved Drug Products with Therapeutic Equivalence Evaluations; this is commonly referred to as the Orange Book.
The FDA's designation of "therapeutic equivalence" indicates that the generic formulation is bioequivalent to the innovator formulation.
This means that drug products are considered to be therapeutic equivalents only if they have identical active ingredients and if they can be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.